Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 20/20 | 1.00 |
| ▸ | RARG | P13631 | 20/20 | 1.00 |
| ▸ | RARA | P10276 | 17/20 | 1.00 |
| ▸ | RXRA | P19793 | 8/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.70 |
| ▸ | GMNN | O75496 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | THPO | P40225 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7829470 | 1.00 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL10551195 | 1.00 | RARB (1.00) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL10693727 | 0.92 | RARB (0.84) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL10693731 | 0.92 | RARB (0.84) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL8460515 | 0.91 | RARB (0.83) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL8460517 | 0.91 | RARB (0.83) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL10566250 | 0.89 | RARB (0.81) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL10566229 | 0.89 | RARB (0.81) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL10693990 | 0.89 | RARB (0.80) | RARBRARGRARARXRAKDM4E | |
| SCHEMBL10693994 | 0.89 | RARB (0.80) | RARBRARGRARARXRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4788213-A | TREATING ACNE AND PSORIASIS | HOFFMAN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | claimed |
| US-20230346743-A1 | COMBINATION CANCER THERAPIES | UNIV OKLAHOMA (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230346743-A1 | COMBINATION CANCER THERAPIES | UNIV OKLAHOMA (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230139842-A1 | NANOCRYSTAL MICROPARTICLES OF POORLY SOLUBLE DRUGS AND METHODS OF PRODUCTION AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2023-05-04 | — | — | US | disclosed |
| US-20230139842-A1 | NANOCRYSTAL MICROPARTICLES OF POORLY SOLUBLE DRUGS AND METHODS OF PRODUCTION AND USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2023-05-04 | — | — | US | disclosed |
| US-7612107-B2 | Such as cancer, diabetes, hemophilia, liver disease, diseases involving human aldehyde dehydrogenase 2, polycystic kidney disease, lysosomal storage diseases, high cholesterol, obesity, high triglycerides, glycoprotein metabolism, and angiogenesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-4826984-A | Heteroarotinoid compounds as anticancer agents | THE BOARD OF REGENTS FOR THE OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGE ACTING FOR AND ON BEHALF OF OKLAHOMA STATE UNIVERSITY (US) | 1989-05-02 | — | — | US | disclosed |
| US-4808597-A | Method for inhibiting the degradation of cartilage | PFIZER INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4788213-A | TREATING ACNE AND PSORIASIS | HOFFMAN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0130795-B1 | CARBOXYLIC ACID DERIVATIVES USEFUL FOR INHIBITING THE DEGRADATION OF CARTILAGE | PFIZER INC. (US) | 1988-11-23 | — | — | EP | disclosed |
| US-4678793-A | ACNE, PSORIASIS, ANTITUMOR | HOFFMANN-LA ROCHE INC. (US) | 1987-07-07 | — | — | US | disclosed |
| EP-0155940-A1 | BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES | SRI INTERNATIONAL (US) | 1985-10-02 | — | — | EP | disclosed |
| WO-1985000806-A1 | BENZONORBORNENYL, BENZOPYRANYL AND BENZOTHIOPYRANYL RETINOIC ACID ANALOGUES | SRI INTERNATIONAL (US) | 1985-02-28 | — | — | WO | disclosed |
| EP-0130795-A2 | Carboxylic acid derivatives useful for inhibiting the degradation of cartilage | PFIZER INC. (US) | 1985-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346743-A1 | COMBINATION CANCER THERAPIES | CCNT2, CDK4, CCNT1 | RARB 2855/4885RARG 3284/4885RARA 3148/4885 |
| US-20230139842-A1 | NANOCRYSTAL MICROPARTICLES OF POORLY SOLUBLE DRUGS AND METHODS OF PRODUCTION AND USE THEREOF | ABCB1, EXOSC5, CHMP4B | RARB 2997/4885RARG 2643/4885RARA 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.